

Leveraging the precisionFDA bioinformatics platform to support developers



Alexis Norris, PhD
Division of Animal Bioengineering and Cellular
Therapies
Center for Veterinary Medicine

Co-authors: Carlo Mercado, PhD; Heather Lombardi, PhD; and Adam Moyer, PhD

Introduction



CVM's Veterinary Innovation Program (VIP)

- Products:
 - Intentional genomic alterations (IGAs) in animals
 - Animal cells, tissues, and cell- or tissue-based products
- Benefits:
 - 1. Intensive review team, senior management, and developer interaction
 - 2. Hands-on assistance
 - 3. Review process benefits
- Aim: use precisionFDA to provide next generation sequencing (NGS) data analysis assistance to developers of IGA products, to:
 - 1. Confirm intended genomic alteration(s)
 - 2. Screen for unintended genomic alterations




FDA **Results** SnpSift & SnpEff FastQC Freebayes Trimmomatic **BWA-MEM** R1.fastq R2.fastq ref.fasta

Conclusion



Animal biotechnology developers can now leverage our suite of Apps through precisionFDA Review Spaces to increase the quality and speed of NGS submissions.



precisionFDA "Review Space"

- 1. Private area for reviewer(s)
- 2. Private area for developer
- 3. Shared area enables secure sharing and analysis of data, as well as ensuring data provenance



Thank you!

